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Edited by Barry HalliwellAbstract Glucocorticoids act synergistically with polycyclic
aromatic hydrocarbons in increasing mRNA and protein levels
of CYP1A1 in rat liver. The action of dexamethasone to modify
CYP1A1 expression has been investigated in adult human hepa-
tocytes. The eﬀect of dexamethasone on the induction of
CYP1A1 by 3-methylcholanthrene is diﬀerent in rat and human
liver cells. Dexamethasone potentiates the induction of CYP1A1
about 3- to 4-fold in rat cells. In human hepatocytes, it reduces
CYP1A1 induction by 50–60% at enzyme protein level, while
it does not have an eﬀect on CYP1A1 mRNA amount.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cytochrome P450 (P450) enzymes play a central role in
biotransformation and elimination of various xenobiotics
(drugs, pesticides, food additives, and chemical pollutants).
Although P450-mediated reactions are primarily detoxiﬁca-
tion processes, certain substrates are metabolically activated
resulting in the generation of reactive intermediates with in-
creased toxicity or mutagenicity. Metabolism by CYP1A en-
zymes often leads to the formation of reactive products
resulting in the DNA-adduct formation of potential human
carcinogens, such as benzo[a]pyrene, arylamines, and haloge-
nated aromatic hydrocarbons [1]. Several of foreign chemicalsAbbreviations: AhR, arylhydrocarbon receptor; GR, glucocorticoid
receptor; GRE, glucocorticoid responsive element; HBSS, Hanks ba-
lanced salt solution; PAH, polycyclic aromatic hydrocarbon; P450,
cytochrome P450
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these enzymes by stimulating P450 gene transcription through
receptor-dependent mechanisms. Transcriptional activation of
CYP1A1 gene requires arylhydrocarbon-receptor (AhR),
which binds planar aromatic ligands such as polycyclic aro-
matic hydrocarbons (PAH) or halogenated biphenyls. AhR-
inducer complex is translocated to the nucleus and forms a
heterodimer with AhR nuclear translocator. The heterodimer
binds to xenobiotic response elements in the promoter of
CYP1A1 gene and functions as transcriptional enhancer
[2–5].
Steroid hormones, especially glucocorticoids and their po-
tent synthetic analog, dexamethasone strongly inﬂuence the
expression of several enzymes involved in the metabolism
and disposition of foreign chemicals [6–9]. The genes regulated
by AhR are modulated by physiological levels of glucocorti-
coids [10]. PAH-dependent expression of CYP1A1 and
UDP-glucuronyltransferase 1A6 (UGT1A6) in rat liver is
potentiated by glucocorticoids, while they repress both basal
and inducible expression of glutathione S-transferase A2
(GSTA2) and NAD(P)H:quinone oxidoreductase (QOR),
and reduce PAH-induced aldehyde dehydrogenase 3 (ALDH3)
expression [11–14]. The inducibility of CYP1A1 by planar aro-
matic compounds (1,2-benzanthracene, 3-methylcholanthrene,
2,3,7,8-tetrachloro-dibenzo-dioxin, and b-naphthoﬂavone) is
potentiated by the action of glucocorticoid receptor (GR).
There are three glucocorticoid responsive elements (GREs) in
the rat CYP1A1 gene within the ﬁrst intron. Exon 1 is a
non-coding region and the initiation codon is located in exon
2. Binding of ligand-activated GR as homodimer to GRE se-
quences interacts with the initiation complex on the promoter
of CYP1A1 gene and enhances the level of induction of
CYP1A1 enzyme by PAHs at the transcriptional level
[15,16]. GRE sequences are conserved within the ﬁrst intron
of rat, mouse and human CYP1A1 [16].
There are natural variations in circulating levels of glucocor-
ticoids which eﬀect not only the temporal expression of devel-
opmentally important genes, but also modulate the regulation
of intermediary metabolism or xenobiotic biotransformation.
In rat, glucocorticoid production is low prior to birth, and in
neonatal life (20–25% of adolescent level), rises at puberty
and declines slowly throughout the life [17,18]. Human fetuses
begin glucocorticoid production at the end of the ﬁrst trimester
and subsequently to birth, roughly follow the pattern observed
in rodents. The degree of potentiation of CYP1A1 inductionblished by Elsevier B.V. All rights reserved.
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pected to be diﬀerent in neonate versus adolescent. Neonatal
rats are responsive to exogenously applied dexamethasone
(more than 2-fold stimulation), whereas adolescent male rats
are relatively unaﬀected, possibly because of the much higher
endogenous levels of glucocorticoids in adult rats [19]. In rat
and human fetal hepatocytes, the inductive eﬀect of 1,2-benz-
anthracene is also enhanced approximately 2.5-fold when
dexamethasone is included in the culture medium [20–22].
The aim of our present work was to establish whether the syn-
thetic glucocorticoid, dexamethasone, is capable to act syner-
gistically with 3-methylcholanthrene in CYP1A1 induction in
adult human hepatocytes.2. Materials and methods
2.1. Chemicals
3-Methylcholanthrene, dexamethasone, RU-486, dimethyl sulfox-
ide, 7-ethoxyresoruﬁn, dicumarol, and phenacetin were the products
of Sigma Chemie (Deisenhofen, Germany). All other chemicals
for hepatocyte isolation and culture were purchased from
Merck (Darmstadt, Germany) and Sigma Chemie (Deisenhofen,
Germany).
2.2. Isolation and culture of hepatocytes
Experiments were carried out by using hepatocytes prepared from
male Wistar rats (weighing 200 g) (ToxiCoop Safety Toxicological
Study Center, Budapest, Hungary). Human livers were obtained from
kidney transplant donors at the Transplantation and Surgery Clinic,
Semmelweis University Budapest (Hungary). Permission of Local Re-
search Ethics Committee was obtained to use human tissues. Clinical
histories of the donors are shown in Table 1. The liver cells were iso-
lated by the method of Bayliss and Skett [23]. Hepatocytes having via-
bility better than 90%, as determined by trypan blue exclusion [24],
were used in all experiments. The cells were plated at a density of
4 · 106 cells/dish onto 60-mm plastic dishes precoated with collagen
in medium described by Ferrini et al. [25]. After 4-h attachment, the
medium was changed and renewed every 24 h thereafter in the absence
of serum. Hepatocytes were exposed to either 3-methylcholanthrene
(3.7 lM), dexamethasone (0–10 lM) or RU-486 (1 and 10 lM) alone
or in combination. The concentration of the vehicle (dimethyl sulfox-
ide) never exceeded 0.1% (v/v). Control cultures received the same vol-
ume of the vehicle as treated cultures.2.3. Enzyme assays
After various periods of treatment in culture, the medium was re-
moved and the hepatocyte monolayers were washed with Hanks bal-
anced salt solution (HBSS). The cells were immediately assayed for
7-ethoxyresoruﬁn O-dealkylase activity of CYP1A in situ using a ki-
netic assay [26]. The assay was initiated by adding HBSS containing
7-ethoxyresoruﬁn (5 lM) and dicumarol (10 lM). The ﬂuorescence
of resoruﬁn formed and released into the extracellular medium was
quantiﬁed at 550 nm excitation and 589 nm emission wavelength.
CYP1A2 activity was measured using the selective substrate, phenace-
tin, as described by Distlerath et al. [27].Table 1
Clinical histories of human donors
Donor Age (years) Sex Race Cause o
HH-024 68 Male Caucasian Subarac
HH-031 58 Male Caucasian Cerebra
HH-033 43 Female Caucasian Cerebra
HH-034 46 Female Caucasian Subarac
HH-053 47 Female Caucasian Subarac
HH-062 17 Female Caucasian Cerebra2.4. Immunoblot analyses
Cultured hepatocytes from 3 to 4 diﬀerent experiments were har-
vested in phosphate buﬀered saline (pH 7.4), and microsomes were pre-
pared according to the method of van der Hoeven and Coon [28].
CYP1A1 amount of hepatocytes was determined by Western blot anal-
ysis using anti-rat CYP1A1 raised in rabbit (primary antibody) and
anti-rabbit IgG (secondary antibody) labeled with horseradish peroxi-
dase. The polyclonal anti-rat CYP1A1 antisera recognized only
CYP1A1 on immunoblots and no cross-reactivity with CYP1A2 was
observed. Immunoreactive proteins were visualized by the enhanced
chemiluminescence method according to the manufacturers instruc-
tions (Amersham Biosciences Trading GmbH, Vienna, Austria).
Protein band intensities were measured by densitometry using Un-
Scan-It-gel software version 5.1 (Silk Scientiﬁc Inc., Orem, UT).
2.5. Preparation and analyses of total RNA
Total RNA was isolated from 107 cultured hepatocytes using Trizol
reagent (Invitrogen, Carlsbad, CA) according to the manufacturers
instructions. RNA (12 lg/lane) was subjected to electrophoresis on a
1% agarose/formaldehyde denaturating gel, transferred onto a nylon
membrane (Bio-Rad, Hercules, CA) and hybridized with radiolabeled
cDNA probes speciﬁc for CYP1A1 or b-actin. The ﬁlters were washed,
exposed to phosphorscreens and quantiﬁed using PhosphorImager and
ImageQuant software (Molecular Dynamics, Sunnyvale, CA).
2.6. Statistical analysis
Enzyme activities are presented as absolute values (pmol/4 · 106
cells/min or pmol/mg microsomal protein/min). Results are reported
as means of activities measured 4–6 cultures ± S.D. For comparison
among several groups, statistical analysis of the results was carried
out using one-way analysis of variance, followed by a two-tailed Stu-
dents t test (GraphPad InStat version 3.0, GraphPad Software, San
Diego, CA). Results were considered statistically signiﬁcant at
P < 0.05.3. Results
Our previous work has clearly demonstrated a potentiating
role for glucocorticoids in the induction of CYP1A1 by PAHs,
such as 1,2-benzanthracene or 3-methylcholanthrene in the li-
ver of fetal or neonatal rats [15,19,20,22]. It has also been
proved that glucocorticoids act synergistically with PAHs in
increasing mRNA and protein levels of CYP1A1 in fetal hu-
man hepatocytes [21]. The actions of synthetic glucocorticoid,
dexamethasone, to modify CYP1A1 induction have been
investigated in adult human hepatocytes. We also wished to
contrast CYP1A1 expression in adult human and rat liver
cells.
3.1. CYP1A1 induction in rat hepatocytes
It was ascertained in preliminary experiments that 3.7 lM of
3-methylcholanthrene was required for maximal induction of
7-ethoxyresoruﬁn O-dealkylase activity in cultured rat hepato-
cytes (data not shown). Consistent with previous reports,
CYP1A1 activity was potently induced by 3-methylcholan-f death Medication
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Fig. 1. The eﬀect of dexamethasone on CYP1A1 induction in rat
hepatocytes. 7-Ethoxyresoruﬁn O-dealkylase activity (EROD) was
determined in untreated (C) or dexamethasone (DXM, 10 lM), 3-
methylcholanthrene (MC, 3.7 lM) and 3-methylcholanthrene + dexa-
methasone (MC + DXM) treated cells cultured for 24 or 48 h.
Activities are average values ± S.D. for hepatocytes of 3 rats.
Signiﬁcant diﬀerence from the control cells was considered at
P < 0.05 (\) and P < 0.001 (\\).
Fig. 3. Representative examples for CYP1A1 protein content in rat
(A) and human (B, HH-024) hepatocytes. Microsomal protein (10 lg/
lane) prepared from control (C) and dexamethasone (DXM, 10 lM) or
3-methylcholanthrene (MC, 3.7 lM) treated cells were subjected to
Western blot analysis using antiCYP1A1 as primary antibodies.
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K. Monostory et al. / FEBS Letters 579 (2005) 229–235 231threne (Fig. 1). The 48-h treatment with 3-methylcholanthrene
resulted in an about 40-fold increase in adult rat cells. Basal
expression of CYP1A1 was apparently increased as a result
of dexamethasone treatment, based on the enzyme activity
and the amount of CYP1A1 protein (Figs. 1 and 3A).
Although, dexamethasone brought about higher levels of
CYP1A1 activity than measured in control hepatocytes, the
elevation was found to be far from the maximal induction
caused by 3-methylcholanthrene. In the presence of dexameth-
asone, 3-methylcholanthrene resulted in a further 3- to 4-fold0
200
400
600
800
1000
1200
*
*
*
*
RAT
0    0.001     0.01   0.1    1     10
ER
O
D
 
a
ct
iv
ity
 (p
m
o
l/4
x1
06
ce
lls
/m
in
)
Dexamethasone concentration (µM)
Fig. 2. The eﬀect of various concentrations of dexamethasone on 7-
ethoxyresoruﬁn O-dealkylase activity (EROD) in adult rat hepato-
cytes. CYP1A1 activity of the cells maintained for 48 h in the presence
of 3-methylcholanthrene (3.7 lM) and of various concentrations of
dexamethasone (0–10 lM) was determined. Activities are average
values ± S.D. for hepatocytes of 3 rats. \ Represents signiﬁcant
diﬀerence from 3-methylcholanthrene treated cells (P < 0.001).
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Fig. 4. Time course of induction of 7-ethoxyresoruﬁn O-dealkylase
activity (EROD) in human hepatocytes by 3-methylcholanthrene (3.7
lM) in the presence or absence of dexamethasone (10 lM) for up to 96
h. The graphs A and B present the same results depicted with diﬀerent
vertical scales. \ Represents signiﬁcant diﬀerence from 3-methylcho-
lanthrene treated (A) or control (B) cells (P < 0.001).
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tocytes relative to 3-methylcholanthrene treatment alone.
3-Methylcholanthrene-mediated CYP1A1 induction was sub-
stantially inﬂuenced by dexamethasone even at a concentration
of 10 nM (Fig. 2). The potentiation of CYP1A1 induction in-
creased sharply and was maximal at a concentration of 1 lM
of dexamethasone.
CYP1A1 enzyme protein could be hardly detected in un-
treated rat hepatocytes, but it was expressed in detectable
amount in dexamethasone treated cells (Fig. 3A). The increase
in 7-ethoxyresoruﬁn O-dealkylase activity caused by 3-methyl-
cholanthrene was reﬂective of a strong increase in CYP1A1
content. Furthermore, addition of dexamethasone resulted in
a further 3.8-fold increase in CYP1A1 protein content.3.2. CYP1A1 expression in adult human hepatocytes
Similar experiments measuring 7-ethoxyresoruﬁn O-dealky-
lase activity and CYP1A1 enzyme protein levels were also per-0
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Fig. 5. Dose–response relationship of dexamethasone suppression of 3-me
human hepatocytes were treated with 3-methylcholanthrene (3.7 lM) and va
O-dealkylase (A) and phenacetinO-deethylase (B) activities were determined i
signiﬁcant diﬀerence from 3-methylcholanthrene treated cells (P < 0.01).formed in adult human hepatocytes. Fig. 4 shows the time
course for induction of CYP1A1 in hepatocytes maintained
up to 96 h. CYP1A activity of control cells was low, but mea-
surable (in the range of 0.5–6.03 pmol/4 · 106 cells/min for dif-
ferent donors) as it was observed in untreated rat hepatocytes.
3-Methylcholanthrene was found to be a potent CYP1A1 in-
ducer in adult human hepatocytes. The maximal CYP1A1
induction of the cells from various donors was diﬀerent (in
the range of 78–203 pmol/4 · 106 cells/min), but the degree
of the elevation of CYP1A1 activity relative to the control cell
population was similar (25–30-fold). In contrast to rats, dexa-
methasone treatment slightly, but signiﬁcantly decreased the
basal activity of human liver cells (by about 30–50%, Fig.
4B). Dexamethasone also reduced the induction of CYP1A1
by 3-methylcholanthrene. 7-Ethoxyresoruﬁn O-dealkylase
activity of the cells treated with 3-methylcholanthrene and
dexamethasone in combination decreased by about 50–60%
as compared to the enzyme activity of 3-methylcholanthrene
treated cells (Fig. 4A). The marked diﬀerence in the activities**
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Fig. 7. Suppressive eﬀect of dexamethasone on 3-methylcholanthrene
mediated induction of CYP1A1 activity (EROD) in the presence of
diﬀerent concentrations of GR antagonist (0, 1, and 10 lM of RU-
486). Human hepatocytes were maintained for 72 h in the presence of
3-methylcholanthrene (MC, 3.7 lM) and dexamethasone (0, 0.1, and 1
lM of DXM). \ Represents signiﬁcant diﬀerence from the activities of
the cells maintained in the absence of dexamethasone (P < 0,01).
K. Monostory et al. / FEBS Letters 579 (2005) 229–235 233of 3-methylcholanthrene and 3-methylcholanthrene + dexa-
methasone treated hepatocytes was observed after 72 h in cul-
ture. The concentration-dependence of repression of CYP1A1
induction was also tested (Fig. 5A). Addition of dexametha-
sone to the medium caused a simple monotonic decline in
3-methylcholanthrene inducible CYP1A1 activity in the con-
centration range between 1011 and 106 M. The maximal
repression of CYP1A1 induction was observed at 107 M
dexamethasone concentration and greater dexamethasone con-
centration did not result in further repression. 1010 M dexa-
methasone was required for half a maximal repression.
Based on antibody inhibition or activity/enzyme protein cor-
relation studies, 7-ethoxyresoruﬁn O-dealkylation appears to
be catalyzed in rat and human both by CYP1A1 and CYP1A2
[29–31]. In order to clarify the contribution of CYP1A2 to
7-ethoxyresoruﬁn O-dealkylase activity in human hepato-
cytes, deethylation of phenacetin, a selective probe substrate
for CYP1A2 [27], was also determined (Fig. 5B). 3-Methylcho-
lanthrene treatment increased phenacetin O-deethylation of
CYP1A2 nearly 4-fold after 72 h in culture. In marked
contrast, dexamethasone did not cause any further changes
in CYP1A2 activity. Even at a concentration of 1 lM,
dexamethasone did not reduce CYP1A2 induction by
3-methylcholanthrene.
Western blot analyses of the microsomes prepared from
adult human hepatocytes revealed responses at the CYP1A1
protein level (Fig. 3B) that were similar to those seen with 7-
ethoxyresoruﬁn O-dealkylase activities (Fig. 4). The content
of CYP1A1 protein in control cells was low, but detectable.
Dexamethasone alone decreased CYP1A1 level, while treat-
ment of the cells with 3-methylcholanthrene resulted in strong
accumulation of CYP1A1 at 72 h in culture. The presence ofFig. 6. The eﬀect of 3-methylcholanthrene and dexamethasone on the
content of CYP1A1 mRNA in adult human hepatocytes (a represen-
tative example from the donor HH-031). The amount of CYP1A1
mRNA (A) relative to b-actin mRNA (B) present in the cells
maintained for 72 h in the absence or presence of 3-methylcholan-
threne (MC, 3.7 lM) and dexamethasone (0.1–10 lM) was determined
by Northern blot. nd, not detected.dexamethasone reduced CYP1A1 inducibility by 3-methylcho-
lanthrene by approximately 50%.
To assess whether the eﬀect of dexamethasone involved a
pretranslational mechanism of action, Northern blot analyses
of mRNA isolated from human cells were performed (Fig.
6). CYP1A1 mRNA was undetectable in hepatocytes incu-
bated in the absence of 3-methylcholanthrene. Treatment of
cells with 3-methylcholanthrene resulted in considerable mes-
sage speciﬁc for CYP1A1. However, the presence of dexameth-
asone did not modulate the amount of CYP1A1 mRNA
inducible by 3-methylcholanthrene.
The role of GR in the synergistic action of dexamethasone in
CYP1A1 induction in rat liver has been proved. Glucocorti-
coid potentiation of CYP1A1 induction by PAHs appears to
be a classical GR-mediated event resulting in enhanced tran-
scriptional activation of the CYP1A1 gene [14–16]. This in-
crease can be abolished in the presence of GR antagonists
[10,21]. In adult human hepatocytes, we found that dexameth-
asone did not aﬀect the transcription of CYP1A1 gene. How-
ever, dexamethasone markedly reduced the amount of
CYP1A1 enzyme protein. The question of whether GR is re-
quired or dexamethasone acts directly in decreasing CYP1A1
protein in human cells was also taken into consideration.
Involvement of the GR in dexamethasone action was investi-
gated by using the strong GR antagonist, RU-486 (Fig. 7).
Co-administration of RU-486 (1 or 10 lM) with 3-methylcho-
lanthrene had no eﬀect on the modulation of CYP1A1 activity
caused by dexamethasone (0.1 or 1 lM). Dexamethasone was
able to reduce CYP1A1 induction by 3-methylcholanthrene in
the presence of RU-486 even at a concentration of two magni-
tude lower, establishing no role for the GR in mediating sup-
pression by dexamethasone.4. Discussion
In agreement with preceding studies [11,32], CYP1A1 in
rat hepatocytes was highly induced by treatment with
234 K. Monostory et al. / FEBS Letters 579 (2005) 229–2353-methylcholanthrene. The present study has also showed that
the induction of CYP1A1 protein and catalytic activity in
adult rat hepatocytes was potentiated by the synthetic gluco-
corticoid analog, dexamethasone. The degree of potentiation
changed over time, being more pronounced at 48 h than at
24 h. CYP1A1 induction was enhanced 3- to 4-fold in the pres-
ence of dexamethasone at as low concentration as 10 nM. Pre-
vious reports have been proved that the molecular mechanism
for the potentiation of PAH-dependent induction of CYP1A1
by glucocorticoids involves the function of GRE sequences lo-
cated in the ﬁrst intron of CYP1A1 gene [15,16]. The mecha-
nism for glucocorticoid-dependent potentiation of CYP1A1
induction has been characterized both in fetal rat and human
hepatocytes [20,21]. The objective of this study was to deter-
mine the glucocorticoid action in CYP1A1 inducibility in adult
human hepatocytes and to contrast the eﬀect in rat versus
human cells.
In contrast to rat, dexamethasone-mediated potentiation of
CYP1A1 induction in adult human hepatocytes was not ob-
served at all. 3-Methylcholanthrene potently activated
CYP1A1 gene resulting in the production of high amount of
CYP1A1 mRNA. However, the addition of dexamethasone
did not bring about further enhancement of CYP1A1 tran-
scription. In spite of the fact that human CYP1A1 gene con-
tains GRE sequences in the ﬁrst intron, the presence of
dexamethasone did not alter CYP1A1 induction by 3-methyl-
cholanthrene at transcriptional level. It has previously been re-
ported that the expression of AhR is suppressed by
dexamethasone [33]. However, 3-methylcholanthrene-medi-
ated transcription of CYP1A1 in adult human hepatocytes
was not modiﬁed in the presence of dexamethasone. It might
be supposed that the amount of AhR was suﬃcient for the
maximal activation of CYP1A1 by 3-methylcholanthrene, even
if its expression was lowered by dexamethasone.
On the other hand, CYP1A1 expression in adult human
hepatocytes was negatively regulated by dexamethasone at
protein level. 7-Ethoxyresoruﬁn O-dealkylation activity was
substantially reduced (by about 50–60%) in the cells exposed
to 3-methylcholanthrene and dexamethasone in combination
relative to 3-methylcholanthrene treated ones. Downregula-
tion of CYP1A1 enzyme was demonstrated in response to
dexamethasone in dose-dependent manner. Dexamethasone
at a concentration of as low as 0.01 nM was able to decrease
signiﬁcantly CYP1A1 activity, and 0.1 lM was required for
maximal repression. The marked decrease of CYP1A1 protein
content of human hepatocytes treated with dexamethasone
and 3-methylcholanthrene corresponded to the reduction of
CYP1A1 activity, indicating that translation or protein stabil-
ity may control CYP1A1 protein levels. Furthermore, the sup-
pression by dexamethasone also occurred in the presence of the
GR antagonist, RU-486, providing evidence for no role of the
GR in dexamethasone-mediated downregulation of CYP1A1
induction. It should also be emphasized that the changes in
7-ethoxyresoruﬁn O-dealkylase activity caused by dexametha-
sone were due to the reduced amount of CYP1A1 enzyme.
CYP1A2 activity was inducible by 3-methylcholanthrene, but
was not aﬀected by the presence of dexamethasone.
In summary, it has been shown that the eﬀect of dexameth-
asone on the induction of CYP1A1 was diﬀerent in adult rat
and human hepatocytes. Dexamethasone potentiated CYP1A1
induction by 3-methylcholanthrene in rat cells. In human
hepatocytes, it had no eﬀect on the transcription of CYP1A1gene, while strongly reduced the activity and the amount of
CYP1A1 enzyme. Evidence presented here suggested that
dexamethasone suppressed CYP1A1 induction at protein level.
This may reﬂect the partial inhibition of de novo synthesis of
CYP1A1 enzyme by dexamethasone or faster degradation of
CYP1A1 protein.
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